Can cutting carbs beat diabetes? new study says maybe
NCT ID NCT05330247
First seen Jun 27, 2026 · Last updated Jul 10, 2026 · Updated 2 times
Summary
This study looks at whether a low-carb, high-protein diet can help people with type 2 diabetes control their blood sugar and lose weight better than a standard diabetes diet. About 100 overweight or obese adults with type 2 diabetes will follow one of the two diets for 12 months. Researchers will measure changes in blood sugar, body weight, and other health markers.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
100 people
The number who actually took part.
- Started
-
Sep 2022
- Finished
-
Jan 2026
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 75 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Men or postmenopausal women aged 18-75 years. Menopause is defined as \>12 months without menses * Overweight or obesity with Body Mass Index (BMI) \>25 kg/m2 * Type 2 diabetes with HbA1c between 48 mmol/mol and 75 mmol/mol (6.5%-9.0%) * Treated with or without metformin, dipeptidyl peptidase 4 (DPP-4) inhibitors, sodium-glucose cotransporter 2 (SGLT-2) inhibitors and/or glucagon-like peptide 1 receptor agonists (GLP-1RA) * Nonsmokers or having quitted smoking \>1 year before the study * Acceptance of regulation of antidiabetic, antihypertensive, and lipid-lowering medications by Cut-DM endocrinologists only Exclusion Criteria: * Ongoing insulin or insulin analog therapy * Severe gut disease as evaluated by the principal investigator e.g. Crohn's disease, Ulcerative colitis, Celiac disease etc. * Extensive surgery to the gut e.g. bariatric surgery, colectomy etc. * Severe heart disease as evaluated by the principal investigator e.g. angina pectoris, coronary heart disease, congestive heart failure (NYHA III-IV) * Severe renal impairment (eGFR\<45 ml/min/1.73 m2 or urine albumin / creatinine ratio \> 300 mg/g) * Severe hepatic impairment as evaluated by the principal investigator (measure of alanine aminotransferase (ALT) and aspartate aminotransferase (AST)) * Cancer within the last 5 years (except basal cell skin cancer or squamous cell skin cancer) * Psychiatric disease, e.g. a history of major depressive or other severe psychiatric disorders * Ongoing systemic corticosteroid treatment, e.g. prednisolone * Reported or documented food allergy, food intolerance, or currently following a particular eating pattern or strong food preferences, not compatible with study participation * Reported or documented alcohol consumption exceeding the recommendations from The Danish Health Authorities * Ongoing treatment with sulfonylureas and/or thiazolidinediones due to the risk of hypoglycemia unless discontinuation is possible, in which case a \>3-month wash-out is mandatory * Hemoglobin \<7 mmol/L for men and \<6 mmol/L for women * Inability, physically and/or mentally, to comply with the procedures required by the study protocol, as evaluated by the principal investigator * Weight change ≥5% the preceding 3 months of screening * Participation in other on-going clinical trials
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Diabetes mellitus, type 2 are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Bispebjerg Hospital
Copenhagen, Copenhagen NV, 2400, Denmark
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Health effects of cottonseed oil versus matched composition diets in humans
- Effectiveness of shared decision Making(SDM)on patients with poor control type 2 diabetes
- A placebo-controlled, proof-of-concept study to evaluate the safety and efficacy of lanifibranor alone and in combination with the sodium-glucose transport protein 2 (SGLT2) inhibitor EmpaGliflozin in patiEnts with non-alcoholic steatohepatitis (NASH) and type 2 diabetes mellitus (T2DM)
- Can Weight-Loss surgery weaken protein digestion in older adults?
- Can pole walking boost heart fitness in diabetic patients?
- Blood tests may reveal hidden healing power of bone marrow stem cells